Go Pro
→ SMX: From Under-the-Radar to Must-Watch! (From Smallcaps Daily) (Ad)tc pixel Free ABOS Stock Alerts

Acumen Pharmaceuticals (ABOS) Financials

Acumen Pharmaceuticals logo
$2.21 -0.04 (-1.78%)
Closing price 04:00 PM Eastern
Extended Trading
$2.22 +0.00 (+0.23%)
As of 04:18 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Acumen Pharmaceuticals

Annual Income Statements for Acumen Pharmaceuticals

This table shows Acumen Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -7.33 -101 -43 -52 -102 -121
Consolidated Net Income / (Loss)		 -7.33 -101 -43 -52 -102 -121
Net Income / (Loss) Continuing Operations		 -7.33 -101 -43 -52 -102 -121
Total Pre-Tax Income 		-7.33 -101 -43 -52 -102 -121
Total Operating Income		 -7.91 -20 -45 -61 -114 -124
Total Gross Profit		 1.44 0.00 0.00 0.00 0.00 0.00
Total Revenue		 1.44 0.00 0.00 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 9.35 20 45 61 114 124
Selling, General & Admin Expense		 1.35 7.28 13 19 20 19
Research & Development Expense		 8.00 12 32 42 94 105
Total Other Income / (Expense), net		 0.59 -81 2.38 8.77 12 2.50
Interest Expense		 - - 0.00 0.58 4.07 4.22
Interest & Investment Income		 0.00 0.08 2.39 11 14 7.45
Other Income / (Expense), net		 0.59 -81 -0.01 -1.44 1.44 -0.73
Basic Earnings per Share		 ($17.48) ($5.02) ($1.06) ($1.08) ($1.71) ($2.00)
Weighted Average Basic Shares Outstanding		 419.12K 20.06M 40.60M 48.61M 60.01M 60.56M
Diluted Earnings per Share		 ($17.48) ($5.02) ($1.06) ($1.08) ($1.71) ($2.00)
Weighted Average Diluted Shares Outstanding		 419.12K 20.06M 40.60M 48.61M 60.01M 60.56M
Weighted Average Basic & Diluted Shares Outstanding		 419.12K 20.06M 41.03M 60.08M 60.57M 72.21M

Quarterly Income Statements for Acumen Pharmaceuticals

This table shows Acumen Pharmaceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -13 -16 -15 -21 -30 -37 -29 -41 -26 -25 -21
Consolidated Net Income / (Loss)		 -13 -16 -15 -21 -30 -37 -29 -41 -26 -25 -21
Net Income / (Loss) Continuing Operations		 -13 -16 -15 -21 -30 -37 -29 -41 -26 -25 -21
Total Pre-Tax Income 		-13 -16 -15 -21 -30 -37 -29 -41 -26 -25 -21
Total Operating Income		 -16 -18 -18 -24 -32 -40 -30 -42 -27 -25 -21
Total Gross Profit		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 16 18 18 24 32 40 30 42 27 25 21
Selling, General & Admin Expense		 4.86 5.19 5.33 4.85 5.02 5.03 5.10 4.63 4.55 4.67 4.67
Research & Development Expense		 11 13 12 20 27 35 25 37 22 21 16
Total Other Income / (Expense), net		 3.08 1.99 2.90 3.84 2.50 2.44 1.57 0.80 0.06 0.06 0.41
Interest Expense		 0.00 - 1.00 1.00 1.03 1.04 1.02 1.05 1.07 1.09 1.07
Interest & Investment Income		 3.12 3.95 4.01 3.82 3.50 2.99 2.47 2.02 1.64 1.32 1.06
Other Income / (Expense), net		 -0.04 -1.38 -0.10 1.03 0.02 0.49 0.13 -0.17 -0.51 -0.17 0.42
Basic Earnings per Share		 ($0.24) ($0.28) ($0.25) ($0.34) ($0.50) ($0.62) ($0.48) ($0.68) ($0.44) ($0.40) ($0.33)
Weighted Average Basic Shares Outstanding		 54.23M 48.61M 59.81M 60.08M 60.08M 60.01M 60.53M 60.57M 60.57M 60.56M 63.22M
Diluted Earnings per Share		 ($0.24) ($0.28) ($0.25) ($0.34) ($0.50) ($0.62) ($0.48) ($0.68) ($0.44) ($0.40) ($0.33)
Weighted Average Diluted Shares Outstanding		 54.23M 48.61M 59.81M 60.08M 60.08M 60.01M 60.53M 60.57M 60.57M 60.56M 63.22M
Weighted Average Basic & Diluted Shares Outstanding		 57.91M 60.08M 60.08M 60.08M 60.08M 60.57M 60.57M 60.57M 60.57M 72.21M 72.23M

Annual Cash Flow Statements for Acumen Pharmaceuticals

This table details how cash moves in and out of Acumen Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 37 78 7.94 -63 -31 18
Net Cash From Operating Activities		 -7.45 -18 -35 -43 -86 -116
Net Cash From Continuing Operating Activities		 -7.45 -18 -35 -43 -86 -116
Net Income / (Loss) Continuing Operations		 -7.33 -101 -43 -52 -102 -121
Consolidated Net Income / (Loss)		 -7.33 -101 -43 -52 -102 -121
Depreciation Expense		 0.00 0.00 0.03 0.06 0.06 0.06
Amortization Expense		 0.00 0.16 0.62 -3.12 -4.90 -0.68
Non-Cash Adjustments To Reconcile Net Income		 0.08 1.18 5.49 10 20 6.81
Changes in Operating Assets and Liabilities, net		 -0.20 81 1.55 2.18 0.70 -0.39
Net Cash From Investing Activities		 0.00 -104 39 -172 48 134
Net Cash From Continuing Investing Activities		 0.00 -104 39 -172 48 134
Purchase of Property, Plant & Equipment		 0.00 -0.04 -0.16 -0.02 -0.02 -0.09
Purchase of Investments		 0.00 -104 -42 -251 -171 -38
Sale and/or Maturity of Investments		 - 0.00 81 79 219 172
Net Cash From Financing Activities		 45 200 3.91 152 6.93 -0.03
Net Cash From Continuing Financing Activities		 45 200 3.91 152 6.93 -0.03
Issuance of Common Equity		 0.00 169 3.79 122 7.94 0.00
Other Financing Activities, net		 0.00 1.88 0.12 0.33 -1.01 -0.03
Cash Interest Paid		 0.00 0.00 0.00 0.17 2.97 2.94
Cash Income Taxes Paid		 0.00 0.00 0.00 0.00 0.00 0.00

Quarterly Cash Flow Statements for Acumen Pharmaceuticals

This table details how cash moves in and out of Acumen Pharmaceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 18 -28 -20 21 -35 2.44 -5.47 6.65 10 7.16 -2.19
Net Cash From Operating Activities		 -13 -8.31 -18 -17 -25 -27 -34 -32 -30 -19 -24
Net Cash From Continuing Operating Activities		 -13 -8.20 -18 -17 -25 -27 -34 -32 -30 -19 -24
Net Income / (Loss) Continuing Operations		 -13 -16 -15 -21 -30 -37 -29 -41 -26 -25 -21
Consolidated Net Income / (Loss)		 -13 -16 -15 -21 -30 -37 -29 -41 -26 -25 -21
Depreciation Expense		 0.01 0.02 0.02 0.02 0.02 0.01 0.02 0.02 0.02 0.01 0.01
Amortization Expense		 -0.68 -1.88 -1.74 -1.43 -1.35 -0.39 -0.56 -0.03 -0.24 0.14 0.06
Non-Cash Adjustments To Reconcile Net Income		 -1.04 7.05 0.76 6.32 8.26 4.92 -1.22 2.41 1.99 3.63 -0.16
Changes in Operating Assets and Liabilities, net		 1.76 3.11 -2.02 -0.92 -1.76 5.39 -3.57 6.72 -5.80 2.26 -3.31
Net Cash From Investing Activities		 -92 -49 -9.20 38 -10 30 29 38 41 26 -14
Net Cash From Continuing Investing Activities		 -92 -49 -9.20 38 -10 30 29 38 41 26 -14
Purchase of Property, Plant & Equipment		 -0.01 -0.01 -0.01 -0.01 - - -0.08 -0.01 - - 0.00
Purchase of Investments		 -127 -72 -45 -12 -99 -15 -35 -3.01 - - -41
Sale and/or Maturity of Investments		 35 23 36 50 88 45 64 42 41 26 27
Net Cash From Financing Activities		 123 29 7.11 -0.13 -0.04 -0.01 -0.04 - - 0.00 36
Net Cash From Continuing Financing Activities		 123 29 7.11 -0.13 -0.04 -0.01 -0.04 - - 0.00 36
Issuance of Common Equity		 122 -0.39 7.94 - - - 0.00 - - - 36
Other Financing Activities, net		 0.47 - -0.83 -0.13 -0.04 -0.01 -0.04 - - 0.00 -0.00
Cash Interest Paid		 - 0.17 0.76 0.74 0.74 0.74 0.72 0.74 0.74 0.73 0.72
Cash Income Taxes Paid		 - - 0.00 - - - 0.00 - - - 0.00

Annual Balance Sheets for Acumen Pharmaceuticals

This table presents Acumen Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 44 230 197 310 239 123
Total Current Assets		 44 199 180 247 178 122
Cash & Equivalents		 44 122 130 67 36 54
Short-Term Investments		 0.00 72 48 177 136 63
Prepaid Expenses		 0.54 4.42 2.72 3.09 6.75 5.39
Plant, Property, & Equipment, net		 0.00 0.04 0.17 0.00 0.00 0.00
Total Noncurrent Assets		 0.00 32 16 63 61 0.58
Other Noncurrent Operating Assets		 0.00 0.01 0.26 0.72 0.72 0.58
Total Liabilities & Shareholders' Equity		 44 230 197 310 239 123
Total Liabilities		 6.37 5.15 7.81 43 57 52
Total Current Liabilities		 0.95 5.15 7.81 13 28 30
Short-Term Debt		 - - - - 0.00 8.77
Accounts Payable		 0.95 5.00 1.64 1.38 5.65 0.55
Accrued Expenses		 - 0.15 6.07 11 22 21
Total Noncurrent Liabilities		 5.41 0.00 0.00 30 30 22
Long-Term Debt		 - - 0.00 30 29 22
Commitments & Contingencies		 - 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -19 225 189 267 182 70
Total Preferred & Common Equity		 -19 225 189 267 182 70
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 -19 225 189 267 182 70
Common Stock		 8.37 353 360 489 507 517
Retained Earnings		 -27 -128 -170 -223 -325 -446
Accumulated Other Comprehensive Income / (Loss)		 - -0.23 -0.75 0.31 -0.05 0.08

Quarterly Balance Sheets for Acumen Pharmaceuticals

This table presents Acumen Pharmaceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 286 301 289 267 204 172 142 134
Total Current Assets		 219 256 267 208 155 148 132 133
Cash & Equivalents		 95 47 68 33 30 37 47 52
Short-Term Investments		 121 206 193 167 119 107 80 77
Prepaid Expenses		 3.16 3.32 6.44 7.29 5.80 5.04 5.54 4.70
Plant, Property, & Equipment, net		 0.12 0.12 0.11 0.09 0.00 0.00 0.00 0.00
Total Noncurrent Assets		 68 45 22 59 50 23 10 0.54
Other Noncurrent Operating Assets		 0.38 0.91 0.99 0.70 0.74 0.70 0.63 0.54
Total Liabilities & Shareholders' Equity		 286 301 289 267 204 172 142 134
Total Liabilities		 6.10 39 45 50 49 55 49 46
Total Current Liabilities		 6.10 8.47 15 20 19 25 22 29
Short-Term Debt		 - - - - - - 3.60 14
Accounts Payable		 1.36 3.08 4.21 2.34 1.06 2.10 0.68 1.66
Accrued Expenses		 4.73 5.27 11 17 18 23 18 13
Total Noncurrent Liabilities		 0.00 30 30 30 30 30 27 17
Long-Term Debt		 - 30 29 30 30 30 27 17
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 280 262 244 217 156 117 93 87
Total Preferred & Common Equity		 280 262 244 217 156 117 93 87
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 280 262 244 217 156 117 93 87
Common Stock		 487 500 502 505 509 512 514 555
Retained Earnings		 -206 -238 -258 -288 -354 -395 -421 -467
Accumulated Other Comprehensive Income / (Loss)		 -0.51 -0.14 -0.16 0.52 0.02 0.02 0.11 0.02

Annual Metrics And Ratios for Acumen Pharmaceuticals

This table displays calculated financial ratios and metrics derived from Acumen Pharmaceuticals' official financial filings.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 0.00 40,470,323.00 40,925,284.00 57,910,461.00 60,079,778.00 60,573,425.00
DEI Adjusted Shares Outstanding		 0.00 40,470,323.00 40,925,284.00 57,910,461.00 60,079,778.00 60,573,425.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 -2.49 -1.05 -0.90 -1.70 -2.00
Growth Metrics		 - - - - - -
Revenue Growth		 0.00% -100.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 0.00% -1,272.25% 55.64% -47.20% -78.87% -6.62%
EBIT Growth		 0.00% -1,274.42% 55.06% -38.31% -79.89% -10.64%
NOPAT Growth		 0.00% -147.52% -130.99% -35.15% -86.49% -8.61%
Net Income Growth		 0.00% -1,273.46% 57.40% -22.20% -95.39% -18.57%
EPS Growth		 0.00% 71.28% 78.88% -1.89% -58.33% -16.96%
Operating Cash Flow Growth		 0.00% -141.09% -95.72% -22.50% -100.20% -34.01%
Free Cash Flow Firm Growth		 0.00% 0.00% -47.58% -37.42% -81.35% -32.97%
Invested Capital Growth		 0.00% 88.22% -593.46% -102.23% -114.98% 24.72%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% 0.00% -15.70% -12.76% -17.81% 10.23%
EBIT Q/Q Growth		 0.00% 0.00% -14.84% -9.84% -20.62% 9.93%
NOPAT Q/Q Growth		 0.00% 0.00% -14.81% -7.45% -22.72% 10.42%
Net Income Q/Q Growth		 0.00% 0.00% -11.78% -7.45% -25.29% 9.01%
EPS Q/Q Growth		 0.00% 0.00% -100.53% 3.57% -24.82% 9.91%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% -27.42% 6.29% -28.08% 6.57%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 7.12% -24.37% 5.03%
Invested Capital Q/Q Growth		 0.00% 0.00% -31.72% -288.24% -68.82% -24.91%
Profitability Metrics		 - - - - - -
Gross Margin		 100.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 -510.17% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 -550.97% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 -510.17% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 -510.10% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 99.99% 99.92% 94.71% 83.69% 90.90% 97.41%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -19.24% -76.44% -20.71% -22.98% -45.60% -96.20%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 -16.49% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 -16.49% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 9.40% -59.99% -20.71% -22.98% -45.60% -96.20%
Return on Equity Simple (ROE_SIMPLE)		 39.40% -44.68% -22.70% -19.62% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -5.54 -14 -32 -43 -80 -87
NOPAT Margin		 -385.68% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -4.08% -64.46% -5.34% -4.08% -9.41% -24.08%
Return On Investment Capital (ROIC_SIMPLE)		 - - - -14.42% -37.78% -85.32%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 94.08% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 556.89% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 650.97% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -7.33 -101 -45 -63 -113 -125
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -7.33 -101 -45 -66 -117 -125
Valuation Ratios		 - - - - - -
Price to Book Value (P/BV)		 0.00 1.21 1.17 0.83 0.57 1.81
Price to Tangible Book Value (P/TBV)		 0.00 1.21 1.17 0.83 0.57 1.81
Price to Revenue (P/Rev)		 92.85 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 101.82 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.11 0.16 0.44
Long-Term Debt to Equity		 0.00 0.00 0.00 0.11 0.16 0.32
Financial Leverage		 -1.15 -1.02 -1.01 -1.03 -1.07 -1.14
Leverage Ratio		 1.17 1.04 1.03 1.11 1.22 1.43
Compound Leverage Factor		 1.17 1.04 0.98 0.93 1.11 1.40
Debt to Total Capital		 0.00% 0.00% 0.00% 10.07% 13.93% 30.67%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 8.63%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 10.07% 13.93% 22.05%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 148.84% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 -48.84% 100.00% 100.00% 89.93% 86.07% 69.33%
Debt to EBITDA		 0.00 0.00 0.00 -0.46 -0.25 -0.25
Net Debt to EBITDA		 0.00 0.00 0.00 4.21 1.72 0.68
Long-Term Debt to EBITDA		 0.00 0.00 0.00 -0.46 -0.25 -0.18
Debt to NOPAT		 0.00 0.00 0.00 -0.70 -0.37 -0.36
Net Debt to NOPAT		 0.00 0.00 0.00 6.46 2.53 0.99
Long-Term Debt to NOPAT		 0.00 0.00 0.00 -0.70 -0.37 -0.26
Altman Z-Score		 12.38 30.68 16.05 2.32 -1.62 -6.07
Noncontrolling Interest Sharing Ratio		 148.84% 21.52% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - -
Current Ratio		 46.57 38.60 23.08 19.01 6.46 4.07
Quick Ratio		 45.89 37.74 22.73 18.77 6.21 3.89
Cash Flow Metrics		 - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -19 -28 -38 -69 -92
Operating Cash Flow to CapEx		 0.00% -44,902.50% -21,834.16% -239,244.44% -538,843.75% -131,293.18%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 -65.45 -16.95 -21.71
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 -74.12 -21.19 -27.35
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 -74.15 -21.20 -27.37
Efficiency Ratios		 - - - - - -
Asset Turnover		 0.03 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - -
Invested Capital		 -5.72 -0.67 -4.67 -9.44 -20 -15
Invested Capital Turnover		 -0.25 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 0.00 5.04 -3.99 -4.77 -11 5.02
Enterprise Value (EV)		 146 48 28 -54 -99 42
Market Capitalization		 133 274 221 222 103 128
Book Value per Share		 ($44.36) $5.56 $4.61 $4.61 $3.03 $1.16
Tangible Book Value per Share		 ($44.36) $5.56 $4.61 $4.61 $3.03 $1.16
Total Capital		 38 225 189 297 211 102
Total Debt		 0.00 0.00 0.00 30 29 31
Total Long-Term Debt		 0.00 0.00 0.00 30 29 22
Net Debt		 -44 -226 -193 -276 -202 -86
Capital Expenditures (CapEx)		 0.00 0.04 0.16 0.02 0.02 0.09
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -0.30 -0.72 -5.09 -10 -21 -16
Debt-free Net Working Capital (DFNWC)		 43 194 173 234 151 101
Net Working Capital (NWC)		 43 194 173 234 151 92
Net Nonoperating Expense (NNE)		 1.79 87 11 9.57 23 35
Net Nonoperating Obligations (NNO)		 -44 -226 -193 -276 -202 -86
Total Depreciation and Amortization (D&A)		 0.00 0.16 0.66 -3.06 -4.84 -0.63
Debt-free, Cash-free Net Working Capital to Revenue		 -21.03% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 3,027.51% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 3,027.51% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - -
Adjusted Basic Earnings per Share		 $0.00 ($5.02) ($1.06) ($1.08) ($1.71) ($2.00)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 40.47M 40.60M 48.61M 60.01M 60.56M
Adjusted Diluted Earnings per Share		 $0.00 ($5.02) ($1.06) ($1.08) ($1.71) ($2.00)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 40.47M 40.60M 48.61M 60.01M 60.56M
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($5.02) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 20.06M 41.03M 60.08M 60.57M 72.21M
Normalized Net Operating Profit after Tax (NOPAT)		 -5.54 -14 -32 -43 -80 -87
Normalized NOPAT Margin		 -385.68% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 -510.10% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 -107.71 -27.67 -29.49
NOPAT to Interest Expense		 0.00 0.00 0.00 -73.66 -19.62 -20.52
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 -107.74 -27.68 -29.51
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 -73.69 -19.62 -20.54
Payout Ratios		 - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Acumen Pharmaceuticals

This table displays calculated financial ratios and metrics derived from Acumen Pharmaceuticals' official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 57,868,512.00 57,910,461.00 60,079,778.00 60,079,778.00 60,079,778.00 60,079,778.00 60,573,425.00 60,573,425.00 60,573,425.00 60,573,425.00 72,212,758.00
DEI Adjusted Shares Outstanding		 57,868,512.00 57,910,461.00 60,079,778.00 60,079,778.00 60,079,778.00 60,079,778.00 60,573,425.00 60,573,425.00 60,573,425.00 60,573,425.00 72,212,758.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.22 -0.28 -0.25 -0.34 -0.50 -0.62 -0.48 -0.68 -0.44 -0.42 -0.29
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 -50.40% -51.97% -46.02% -80.21% -100.43% -81.71% -57.10% -69.32% 18.84% 36.13% 32.89%
EBIT Growth		 -41.40% -39.33% -36.07% -73.03% -100.50% -96.85% -69.17% -79.53% 16.19% 35.12% 31.45%
NOPAT Growth		 -41.05% -29.74% -35.32% -80.89% -101.17% -114.20% -70.87% -71.24% 17.83% 36.36% 30.36%
Net Income Growth		 -20.98% -28.22% -31.54% -76.89% -129.72% -125.22% -93.61% -99.40% 11.13% 32.34% 27.99%
EPS Growth		 7.69% 12.50% 10.71% -21.43% -108.33% -121.43% -92.00% -100.00% 12.00% 35.48% 31.25%
Operating Cash Flow Growth		 -40.53% 25.79% -75.52% -41.77% -90.59% -227.34% -91.06% -92.40% -23.96% 29.83% 29.29%
Free Cash Flow Firm Growth		 -1,225.81% -36.60% -150.62% -29.68% -5.33% -106.46% 0.51% -46.54% -41.18% -34.33% -39.88%
Invested Capital Growth		 31.39% -102.23% 7.72% -142.71% -394.41% -114.98% -194.59% -138.51% -1.74% 24.72% 23.41%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -21.91% -29.71% 9.81% -26.36% -35.58% -17.59% 22.02% -36.19% 35.01% 7.46% 18.07%
EBIT Q/Q Growth		 -19.17% -23.54% 10.01% -30.60% -38.09% -21.30% 22.67% -38.60% 35.54% 6.10% 18.29%
NOPAT Q/Q Growth		 -19.00% -15.26% 3.85% -37.17% -32.34% -22.72% 23.30% -37.47% 36.50% 4.96% 16.07%
Net Income Q/Q Growth		 -11.60% -27.32% 9.84% -38.08% -44.93% -24.82% 22.50% -42.21% 35.41% 4.96% 17.51%
EPS Q/Q Growth		 14.29% -16.67% 10.71% -36.00% -47.06% -24.00% 22.58% -41.67% 35.29% 9.09% 17.50%
Operating Cash Flow Q/Q Growth		 -10.58% 35.58% -114.81% 7.36% -48.66% -10.65% -25.38% 6.71% 4.22% 37.37% -26.35%
Free Cash Flow Firm Q/Q Growth		 -29.76% 33.80% -56.78% 3.72% -5.40% -29.76% 24.45% -41.82% -1.54% -23.46% 21.33%
Invested Capital Q/Q Growth		 26.73% -288.24% 53.62% -83.98% -49.25% -68.82% 36.45% -48.96% 36.34% -24.91% 35.35%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 80.57% 83.04% 83.19% 87.96% 92.32% 95.00% 95.21% 97.69% 97.89% 99.07% 100.02%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -20.44% -22.98% -25.36% -31.42% -32.83% -45.60% -55.68% -75.71% -85.93% -96.20% -93.23%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -20.44% -22.98% -25.36% -31.42% -32.83% -45.60% -55.68% -75.71% -85.93% -96.20% -93.23%
Return on Equity Simple (ROE_SIMPLE)		 -17.39% 0.00% -21.35% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -11 -13 -12 -17 -23 -28 -21 -29 -19 -18 -15
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -0.72% -1.51% -1.08% -1.64% -2.80% -3.94% -3.47% -6.04% -4.72% -5.21% -4.46%
Return On Investment Capital (ROIC_SIMPLE)		 - -4.36% -4.26% -6.24% -9.15% -13.12% -11.49% -19.89% -14.99% -17.36% -12.49%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -16 -20 -18 -23 -32 -39 -30 -42 -27 -25 -21
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -17 -22 -20 -25 -34 -39 -31 -42 -27 -25 -21
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.86 0.83 0.93 0.60 0.69 0.57 0.43 0.60 1.11 1.81 1.95
Price to Tangible Book Value (P/TBV)		 0.86 0.83 0.93 0.60 0.69 0.57 0.43 0.60 1.11 1.81 1.95
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.11 0.12 0.12 0.14 0.16 0.19 0.26 0.33 0.44 0.35
Long-Term Debt to Equity		 0.00 0.11 0.12 0.12 0.14 0.16 0.19 0.26 0.29 0.32 0.19
Financial Leverage		 -1.01 -1.03 -1.02 -1.03 -1.03 -1.07 -1.04 -1.08 -1.08 -1.14 -1.09
Leverage Ratio		 1.03 1.11 1.11 1.13 1.11 1.22 1.21 1.28 1.32 1.43 1.39
Compound Leverage Factor		 0.83 0.92 0.92 0.99 1.03 1.16 1.15 1.25 1.29 1.42 1.39
Debt to Total Capital		 0.00% 10.07% 10.34% 10.75% 12.02% 13.93% 15.96% 20.33% 24.75% 30.67% 26.19%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 2.91% 8.63% 11.92%
Long-Term Debt to Total Capital		 0.00% 10.07% 10.34% 10.75% 12.02% 13.93% 15.96% 20.33% 21.85% 22.05% 14.28%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 89.93% 89.66% 89.25% 87.98% 86.07% 84.04% 79.67% 75.25% 69.33% 73.81%
Debt to EBITDA		 0.00 -0.46 -0.42 -0.35 -0.30 -0.25 -0.23 -0.21 -0.22 -0.25 -0.27
Net Debt to EBITDA		 0.00 4.21 3.71 3.04 2.30 1.72 1.31 0.93 0.76 0.68 0.85
Long-Term Debt to EBITDA		 0.00 -0.46 -0.42 -0.35 -0.30 -0.25 -0.23 -0.21 -0.19 -0.18 -0.15
Debt to NOPAT		 0.00 -0.70 -0.66 -0.55 -0.46 -0.37 -0.33 -0.30 -0.32 -0.36 -0.39
Net Debt to NOPAT		 0.00 6.46 5.79 4.69 3.52 2.53 1.90 1.35 1.09 0.99 1.21
Long-Term Debt to NOPAT		 0.00 -0.70 -0.66 -0.55 -0.46 -0.37 -0.33 -0.30 -0.28 -0.26 -0.21
Altman Z-Score		 23.33 2.78 3.43 1.47 0.73 -0.60 -1.30 -2.39 -2.58 -3.41 -2.26
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 35.85 19.01 30.20 17.37 10.43 6.46 8.02 5.97 6.02 4.07 4.55
Quick Ratio		 35.33 18.77 29.81 16.95 10.06 6.21 7.72 5.77 5.77 3.89 4.39
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -12 -8.17 -13 -12 -13 -17 -13 -18 -18 -23 -18
Operating Cash Flow to CapEx		 -184,357.14% -59,385.71% -162,354.55% -330,900.00% 0.00% 0.00% -43,191.14% -353,688.89% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 -12.81 -12.28 -12.66 -16.26 -12.46 -17.28 -17.18 -20.84 -16.67
Operating Cash Flow to Interest Expense		 0.00 0.00 -17.86 -16.48 -23.95 -26.24 -33.35 -30.43 -28.55 -17.57 -22.57
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 -17.87 -16.48 -23.95 -26.24 -33.43 -30.44 -28.55 -17.57 -22.57
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -2.43 -9.44 -4.38 -8.05 -12 -20 -13 -19 -12 -15 -9.88
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 1.11 -4.77 0.37 -4.74 -9.59 -11 -8.52 -11 -0.21 5.02 3.02
Enterprise Value (EV)		 -43 -54 -23 -107 -80 -99 -102 -66 -1.82 42 73
Market Capitalization		 240 222 243 145 149 103 67 70 104 128 170
Book Value per Share		 $4.84 $4.61 $4.36 $4.06 $3.62 $3.03 $2.57 $1.93 $1.54 $1.16 $1.21
Tangible Book Value per Share		 $4.84 $4.61 $4.36 $4.06 $3.62 $3.03 $2.57 $1.93 $1.54 $1.16 $1.21
Total Capital		 280 297 292 273 247 211 185 147 124 102 119
Total Debt		 0.00 30 30 29 30 29 30 30 31 31 31
Total Long-Term Debt		 0.00 30 30 29 30 29 30 30 27 22 17
Net Debt		 -283 -276 -266 -252 -229 -202 -168 -136 -105 -86 -97
Capital Expenditures (CapEx)		 0.01 0.01 0.01 0.01 0.00 0.00 0.08 0.01 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -2.93 -10 -5.15 -8.92 -13 -21 -14 -20 -13 -16 -10
Debt-free Net Working Capital (DFNWC)		 213 234 247 252 188 151 136 124 114 101 118
Net Working Capital (NWC)		 213 234 247 252 188 151 136 124 110 92 104
Net Nonoperating Expense (NNE)		 1.73 3.56 2.43 3.47 7.18 9.44 7.54 12 7.89 7.50 5.93
Net Nonoperating Obligations (NNO)		 -283 -276 -266 -252 -229 -202 -168 -136 -105 -86 -97
Total Depreciation and Amortization (D&A)		 -0.67 -1.86 -1.72 -1.41 -1.33 -0.37 -0.54 -0.01 -0.23 0.16 0.07
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.24) ($0.28) ($0.25) ($0.34) ($0.50) ($0.62) ($0.48) ($0.68) ($0.44) ($0.40) ($0.33)
Adjusted Weighted Average Basic Shares Outstanding		 54.23M 48.61M 59.81M 60.08M 60.08M 60.01M 60.53M 60.57M 60.57M 60.56M 63.22M
Adjusted Diluted Earnings per Share		 ($0.24) ($0.28) ($0.25) ($0.34) ($0.50) ($0.62) ($0.48) ($0.68) ($0.44) ($0.40) ($0.33)
Adjusted Weighted Average Diluted Shares Outstanding		 54.23M 48.61M 59.81M 60.08M 60.08M 60.01M 60.53M 60.57M 60.57M 60.56M 63.22M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 57.91M 60.08M 60.08M 60.08M 60.08M 60.57M 60.57M 60.57M 60.57M 72.21M 72.23M
Normalized Net Operating Profit after Tax (NOPAT)		 -11 -13 -12 -17 -23 -28 -21 -29 -19 -18 -15
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 -17.88 -23.26 -31.39 -37.71 -29.56 -40.08 -25.30 -23.34 -19.39
NOPAT to Interest Expense		 0.00 0.00 -12.44 -17.00 -21.99 -26.73 -20.78 -27.94 -17.38 -16.23 -13.85
EBIT Less CapEx to Interest Expense		 0.00 0.00 -17.89 -23.26 -31.39 -37.71 -29.64 -40.08 -25.30 -23.34 -19.39
NOPAT Less CapEx to Interest Expense		 0.00 0.00 -12.45 -17.00 -21.99 -26.73 -20.86 -27.95 -17.38 -16.23 -13.85
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Acumen Pharmaceuticals (NASDAQ: ABOS) remains a pre-revenue clinical-stage biotech with a cash-heavy balance sheet, but its quarterly results show continued large operating losses and ongoing cash burn. Over the last four years, the biggest story has been the company’s ability to fund its development work through equity raises and investment securities rather than revenue generation.

Positive trends:

  • ABOS ended Q1 2026 with $133.1 million in current assets, including $51.8 million in cash and equivalents and $76.6 million in short-term investments.
  • The company still has a sizable liquidity cushion relative to its current liabilities, with $87.5 million in common equity at the end of Q1 2026.
  • Q1 2026 financing activity added $35.7 million in cash, mainly from issuance of common equity, which helped offset operating and investing cash outflows.
  • Research and development spending dropped to $16.5 million in Q1 2026 from $20.5 million in Q4 2025 and $21.0 million in Q3 2025, suggesting some moderation in quarterly burn.
  • Operating cash burn improved sequentially, with cash used in operations narrowing to $24.1 million in Q1 2026 from $19.1 million in Q4 2025 and $30.5 million in Q3 2025.
  • The company has kept interest income meaningful by maintaining a large investment portfolio, which helped partially offset losses in several periods.

Neutral observations:

  • ABOS reported no revenue across every quarter provided, so the company is still entirely dependent on financing and capital markets to fund operations.
  • The balance sheet has shifted materially from long-term investments in 2024 to more cash and short-term investments in 2026, indicating a more liquid but potentially less income-generating asset mix.
  • Share counts have trended higher over time, reflecting repeated equity issuance, but this is common for development-stage biotech companies.
  • Quarterly net losses have remained large, but they have fluctuated rather than followed a straight downward line.

Negative trends:

  • ABOS posted a Q1 2026 net loss of $20.7 million, or $0.33 per share, showing the company is still far from profitability.
  • Over the last several quarters, operating losses have remained consistently heavy, ranging from roughly $17.8 million in Q1 2024 to $39.6 million in Q4 2024 and $21.1 million in Q1 2026.
  • Retained earnings were deeply negative at $(467.2) million in Q1 2026, underscoring the cumulative impact of years of losses.
  • Total liabilities reached $46.2 million in Q1 2026, including $14.1 million of short-term debt and $16.9 million of long-term debt.
  • Cash and equivalents fell from $68.0 million in Q2 2025 to $51.8 million in Q1 2026, even after the company raised equity capital.
  • The company’s asset base is shrinking compared with 2024, when total assets were much higher due to larger investment holdings.
  • Operating cash flow remained negative in every period shown, including $(24.1) million in Q1 2026 and $(34.1) million in Q1 2024.

Bottom line: ABOS still looks like a classic clinical-stage biotech story: meaningful cash resources, no sales, and persistent losses. The near-term focus for investors is whether the company can advance its pipeline without forcing excessive dilution. For now, the balance sheet gives it some runway, but the operating trend remains firmly negative.

07/20/26 02:41 PM ETAI Generated. May Contain Errors.

Acumen Pharmaceuticals Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Acumen Pharmaceuticals' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Acumen Pharmaceuticals' net income appears to be on an upward trend, with a most recent value of -$121.34 million in 2025, rising from -$7.33 million in 2020. The previous period was -$102.33 million in 2024. Find out what analysts predict for Acumen Pharmaceuticals in the coming months.

Acumen Pharmaceuticals' total operating income in 2025 was -$123.83 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $123.83 million

Over the last 5 years, Acumen Pharmaceuticals' total revenue changed from $1.44 million in 2020 to $0.00 in 2025, a change of -100.0%.

Acumen Pharmaceuticals' total liabilities were at $52.40 million at the end of 2025, a 8.3% decrease from 2024, and a 723.0% increase since 2020.

In the past 5 years, Acumen Pharmaceuticals' cash and equivalents has ranged from $35.63 million in 2024 to $130.10 million in 2022, and is currently $53.99 million as of their latest financial filing in 2025.

Over the last 5 years, Acumen Pharmaceuticals' book value per share changed from -44.36 in 2020 to 1.16 in 2025, a change of -102.6%.


Related Companies

Financial statements for NASDAQ:ABOS last updated on 7/9/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
SMX: From Under-the-Radar to Must-Watch!
SMX (Security Matters) PLC is building Digital Material Passport technology that embeds molecular-level marker...
Smallcaps Daily | Sponsoredtc pixel
Buy this stock tomorrow
Marc Chaikin, founder of Chaikin Analytics, is flagging a little-known company that just secured a partnership...
Chaikin Analytics | Sponsoredtc pixel
Man who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown”
In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon advi...
Paradigm Press | Sponsoredtc pixel
American’s Biggest Threat Is Here
This feels like one of those ''where were you when Kennedy was shot'' moments. It felt like a moment in time, ...
Goldco Direct, LLC | Sponsoredtc pixel
Do this before December or regret it
Porter Stansberry believes President Trump will use the December G20 Summit in Miami to unveil a radical monet...
Porter & Company | Sponsoredtc pixel
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...
Profits Run | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
27 insiders just called an emergency meeting
A staggering $122 million traded on Polymarket and another $64 million on Kalshi on whether America would win ...
Crypto 101 Media | Sponsoredtc pixel